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INTRODUCTION

Type 2 diabetes mellitus (T2DM) is a progressive disease, with increasing insulin resistance (IR)
The DPP-4 enzyme rapidly inactivates the incretin hormones, glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) [1] , which play a crucial role in glucose homeostasis [2, 3] . DPP-4 inhibitors bind to the catalytic site of DPP-4, resulting in prolonged inhibition of the enzyme, thus, raising levels of intact GLP-1 and GIP [4] . The resulting improvement in islet dysfunction is a key mechanism underlying the glucoselowering mechanism of DPP-4 inhibitors [4] .
There is also a potential beta-cell preservation effect, as judged from rodent models, in which an increase in beta-cell mass through stimulation of neogenesis and proliferation, as well as an inhibition of apoptosis, has been seen with GLP-1/DPP-4 inhibitors [5, 6] .
While DPP-4 inhibitor therapy has been studied in a variety of clinical study settings [7] [8] [9] [10] , the optimal stage for their use in the course of T2DM is still under debate. Based on the known effects on beta-cell function, there is frequently a perception that treatment with these agents may be less efficacious with increasing disease progression, due to loss of beta-cell function, and with increasing IR, where beta-cell function is proportionally less important.
The present paper, therefore, aimed to evaluate the impact of such factors (i.e., T2DM duration and duration of previous therapy, and IR and body mass index [BMI]) on the efficacy of the DPP-4 inhibitor, vildagliptin, using a pooled database of studies in add-on therapy to metformin. Vildagliptin is a DPP-4 inhibitor that has been extensively studied in a large clinical program, with proven efficacy and a well-established safety profile [8, [11] [12] [13] [14] . The present paper reports the results of these new pooled subgroup analyses with vildagliptin.
METHODS
Populations
The efficacy analyses included all randomized, double-blind, controlled, parallel-group add-on to metformin studies with vildagliptin 50 mg twice daily (b.i.d.) (the highest approved and most commonly used dose of the drug). A total of four studies were pooled (termed 'pooled add-on to metformin population').
The efficacy population comprised all patients who were included in the respective primary efficacy populations of the individual studies [15] [16] [17] [18] . Data collected in the first 24 weeks of treatment from these studies were included in the analyses. Details of the study designs are summarized in Appendix Table 3 and the individual study publications [15] [16] [17] [18] . [19] .
Data Analysis
The total number of patients, and demography and baseline characteristics were recorded. While the SU group had a comparable number of patients to the vildagliptin group, the two other comparator groups in the studies (placebo and thiazolidinedione [TZD]) comprised only 2.6% and 5.7%, respectively, of patients in the pooled population; thus, not representing meaningful reference groups to be analyzed.
Ethics and Good Clinical Practice
All study participants provided written informed consent. All protocols were approved by the independent ethics committee/ institutional review board at each study site or country. All studies were conducted using good clinical practice and in accordance with the Declaration of Helsinki. Table 1 The impact of disease progression on the efficacy of vildagliptin was evaluated by stratification according to three T2DM duration categories, 0 to\1 year (mean = 0.6 years), C1 to\5 years (mean = 2.9 years), and C5 years (mean = 9.7 years). In addition, the duration of (±SE) was reduced by -0.64 ± 0.05% (baseline 7.47 ± 0.06%), -0.60 ± 0.03% (baseline 7.65 ± 0.03%), and -0.69 ± 0.03% (baseline 7.88 ± 0.03%) in the T2DM duration subgroups of 0 to\1, C1 to\5, and C5 years, respectively. 
RESULTS
Demography
Efficacy by Subgroups
DISCUSSION
The present paper evaluated the impact of IR, BMI, disease duration, and duration of metformin use on the efficacy of vildagliptin in patients with T2DM treated with metformin. The pooled analysis found similar efficacy of vildagliptin independent of these factors, indicating that patients with higher IR, more obese patients, and patients with long-standing T2DM can benefit from treatment with the DPP-4 inhibitor, vildagliptin, in combination with metformin.
These data can provide relevant information for the use of vildagliptin in clinical practice, in particular given the not uncommon perception that treatment with DPP-4 inhibitors may be less beneficial with increasing disease progression, due to loss of beta-cell function, and with increasing IR, where beta-cell function is proportionally less important. The notion of DPP-4 inhibitors being more beneficial in patients with shorter disease duration may at least be in part related to the promise from animal models [5, 6] that these incretin-based therapies may be able to interfere with disease progression if used as an early intervention, when sufficient beta-cell function/mass can be still be preserved or restored, which raised particular attention when these drugs initially became available. On the other hand, consistent with the findings of the present report, vildagliptin has meanwhile been shown to be efficacious across a wide disease spectrum, including add-on therapy to insulin as well as patients with renal impairment, both involving patients with long-standing T2DM (mean T2DM duration 13-17 years) [20] [21] [22] [23] .
In this context, it is important to keep in mind that vildagliptin, in addition to improving beta-cell function, also enhances alpha-cell function (i.e., suppresses inappropriate glucagon secretion as shown after oral glucose and meal ingestion [24] [25] [26] ), with the changes in islet hormone (i.e., increased insulin and reduced glucagon) secretion leading to a profound effect to suppress hepatic glucose production [27] . Furthermore, vildagliptin is associated with reduced insulin resistance due to reduced lipotoxicity [28, 29] . Thus, a variety of pancreatic and extra-pancreatic effects are active to support the efficacy of vildagliptin [4] . Similar results to those seen with vildagliptin plus metformin were also seen in the group of patients treated with SUs in combination with metformin, who were analyzed as a reference group. The common perception is that both DPP-4 inhibitors and SUs tend to be more efficacious in lean than obese individuals and the reverse is true for TZDs. The data in this study do not support this perception about vildagliptin and SUs, and the authors are unaware of any data that does. In contrast, addition of the TZD, rosiglitazone, to metformin was indeed shown to be most efficacious in obese, insulin-resistant patients, as expected from the mechanism of action [30] . Similar results were also seen with pioglitazone added to SU therapy in a small Japanese study;
HbA 1c was decreased considerably more in the Homa IR C4 category compared to the \4 subgroup [31] . 
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